Authors
Marc A Pfeffer, John JV McMurray, Eric J Velazquez, Jean-Lucien Rouleau, Lars Køber, Aldo P Maggioni, Scott D Solomon, Karl Swedberg, Frans Van de Werf, Harvey White, Jeffrey D Leimberger, Marc Henis, Susan Edwards, Steven Zelenkofske, Mary Ann Sellers, Robert M Califf
Publication date
2003/11/13
Journal
New England Journal of Medicine
Volume
349
Issue
20
Pages
1893-1906
Publisher
Massachusetts Medical Society
Description
Background
Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients.
Methods
Patients receiving conventional therapy were randomly assigned, 0.5 to 10 days after acute myocardial infarction, to additional therapy with valsartan (4909 patients), valsartan plus captopril (4885 patients), or captopril (4909 patients). The primary end point was death from any cause.
Results
During a median follow-up of 24.7 months, 979 patients in the valsartan group died, as did 941 patients in the valsartan-and-captopril group and 958 patients in the captopril group …
Total citations
Scholar articles
MA Pfeffer, JJV McMurray, EJ Velazquez, JL Rouleau… - New England Journal of Medicine, 2003
MA Pfeffer, SC Greaves, MO Arnold, RJ Glynn… - Circulation, 1997